Angiotensin 1-7 + Adrenomedullin Peptide Stack

The Angiotensin 1-7 and Adrenomedullin peptide stack represents a synergistic approach to cardiovascular research, leveraging the distinct yet complementary mechanisms of both peptides. Angiotensin 1-7 is primarily involved in counteracting the vasoconstrictive effects of angiotensin II, while Adrenomedullin is known for its potent vasodilatory properties. Together, these peptides may enhance vasodilation and provide cardioprotective effects, potentially addressing the limitations of targeting each pathway in isolation. This combination is particularly relevant for studying conditions such as hypertension and heart failure, where both vasodilation and cardiac protection are essential for improving patient outcomes.

Angiotensin 1-7 is a 7-amino-acid peptide (sequence: Asp-Arg-Val-Tyr-Ile-His-Pro, MW ~899.0 g/mol) generated through the action of ACE2 on angiotensin II. Its role as a counter-regulatory component of the renin-angiotensin system positions it as a critical player in cardiovascular health. Studies indicate that Angiotensin 1-7 mitigates the adverse effects of angiotensin II, including vasoconstriction and inflammation, by activating the Mas receptor (MasR). This activation promotes nitric oxide (NO) release and enhances endothelial function through the PI3K/Akt/eNOS signaling pathway. However, its rapid degradation by peptidases such as ACE and neprilysin limits its therapeutic potential, with a plasma half-life of less than 30 seconds. Ongoing research aims to explore strategies to enhance its stability and efficacy.

Adrenomedullin, a 52-amino-acid peptide (MW ~6028 g/mol), was first identified in human pheochromocytoma tissue and has since garnered attention for its extensive cardiovascular effects. This peptide exhibits significant vasodilatory, natriuretic, and cardioprotective properties, and is being investigated as a biomarker (MR-proADM) for sepsis and heart failure prognosis. Adrenomedullin's signaling occurs through the calcitonin receptor-like receptor (CLR) in conjunction with receptor activity-modifying proteins (RAMP2/RAMP3), which activate adenylyl cyclase, leading to increased cAMP and subsequent NO release. Although its half-life in plasma is approximately 22 minutes, the mid-regional fragment (MR-proADM) offers a more stable alternative for clinical assessment. Research continues to elucidate the full therapeutic potential of Adrenomedullin, particularly in the context of cardiovascular diseases.